Nuanyang Medical Completes Tens of Millions RMB Pre-A Financing Round, Emerging as a Leading Neurointerventional Device Company in China

VCBeat (WeChat ID: vcbeat) has learned that Nuanyang Medical, a medical device company specializing in neurointerventional procedures, has completed a Pre-A financing round amounting to tens of millions of RMB. The investment was jointly made by China Growth Capital and RAYS, with Ruiling Capital serving as the exclusive financial advisor.

Nuanyang Medical, established in January 2019, is a leading domestic provider of neurointerventional therapeutic devices. The company develops, manufactures, and markets neurointerventional/implantable devices and their accessories through minimally invasive interventional implantation techniques, with its product portfolio covering the two major fields of ischemic and hemorrhagic stroke.

Stroke, commonly known as "brain stroke," refers to acute cerebral circulatory disturbance caused by stenosis, occlusion, or rupture of intracranial arteries due to various predisposing factors. It is primarily categorized into ischemic stroke and hemorrhagic stroke. Stroke ranks among the top three causes of death in China. Reports indicate that in recent years, nearly 2 million Chinese residents die from stroke annually, accounting for 22.8% of all deaths. The average age of onset is 63 years, which is 10 years earlier than in the United States, with a trend toward affecting younger populations.

Neurointerventional procedures have become one of the mainstream treatments for stroke. The neurointerventional market in the coming decade will mirror the cardiovascular interventional market of ten years ago, exhibiting a trend of rapid growth. In 2017, the demand for neurointerventional stent systems in China was approximately 20,000 units, growing at an annual rate of 5%–6%. However, the sector still faces clinical shortages of interventional devices for stroke and import monopoly issues, creating an urgent market need for high-quality domestically produced stroke intervention devices.

Nuanyang Medical focuses on the clinical challenges and current technological landscape of stroke treatment. It has independently developed flow diverter devices and embolization stent systems, covering both ischemic and hemorrhagic cerebrovascular diseases. With significant technological advantages, the company provides comprehensive solutions for stroke care and has established an integrated platform encompassing R&D, manufacturing, and clinical application.

All core team members of Nuanyang Medical possess over ten years of experience in the design and development of medical devices. As early pioneers in neurointerventional research in China, they boast extensive industry resources. The company’s R&D center is located in Shanghai Zhangjiang Hi-Tech Park, gathering diverse innovative R&D talent; its production base is situated in Nantong Science and Technology City, Jiangsu Province, featuring a 1,000-square-meter independent facility and Class 10,000 cleanrooms. With strong professional manufacturing capabilities, the annual production capacity reaches 300,000 units.

Leveraging advanced technology and a seasoned team, Nuanyang Medical has achieved rapid progress since its establishment in early 2019. The company has completed the design and development of its first product, gradually initiating type testing, animal trials, and new product R&D. Nuanyang Medical secured early-stage investment from China Growth Capital and RAYS, underscoring the recognition by professional healthcare investment institutions of the company’s strategic direction, product portfolio, and core technologies.

China Growth Capital is one of China’s premier early-stage investment firms, providing venture capital to startups in their initial phases. While primarily focused on the Chinese market, it also maintains a presence in Silicon Valley, USA. Since its establishment in 2006, China Growth Capital has concentrated on early-stage investments in technology and frontier innovations, as well as industry and consumer sectors. Leveraging its extensive resources and expertise, the firm assists its portfolio companies with strategic planning, business expansion, and team building. China Growth Capital has received numerous awards from platforms such as 36Kr and Iyiou, including recognition as one of the Top 50 Venture Capital Firms in China, one of the Top 30 Leading Venture Capital Firms in China, and one of the Top 10 Best Investment Firms in China’s FinTech Industry.

RAYS was established in Beijing in September 2014, focusing on incubating and supporting innovative startups in the healthcare sector. The medical funds initiated and managed by RAYS are positioned as professional early-stage venture capital vehicles dedicated to the healthcare industry, investing in high-potential companies involved in medical devices, biotechnology, innovative drug R&D, and other healthcare-related fields. RAYS has been recognized as one of the Top 10 Emerging Investment Institutions in China’s Healthcare Sector by 36Kr and ranked among the Top 50 Early-Stage Investment Institutions Most Welcomed by LPs in China.

RuiLing Capital, established in July 2018, is a boutique financial advisory (FA) firm primarily providing equity-related investment and financing as well as financial consulting services to early-stage healthcare startups from Pre-A to Pre-C rounds. The team comprises seasoned investment banking and investment professionals in China, boasting extensive medical industry resources and networks, keen insights, and profound expertise across numerous healthcare subsectors. With mature methodologies and a comprehensive service workflow, the team precisely connects clients with high-quality resources, supports business development, optimizes organizational structures, and drives company valuation growth. To date, the firm has served more than ten companies and facilitated investment transactions totaling hundreds of millions of yuan.